biostudies-literatureEdlow BLNational Institute of Neurological Disorders and StrokeNICHD NIH HHSNIH Office of the DirectorAstraZeneca FoundationJames S. McDonnell FoundationMind Science FoundationBIAL FoundationKing Baudouin Foundation United StatesTiny Blue Dot FoundationBelgian National Fund for Scientific ResearchNINDS NIH HHSH2020 Marie Skłodowska-Curie ActionsNeurocritical Care Society68-85https://www.ebi.ac.uk/biostudies/studies/S-EPMC8266715biostudies-literatureUnknown35(Suppl 1)<h4>Background/objective</h4>For patients with disorders of consciousness (DoC) and their families, the search for new therapies has been a source of hope and frustration. Almost all clinical trials in patients with DoC have been limited by small sample sizes, lack of placebo groups, and use of heterogeneous outcome measures. As a result, few therapies have strong evidence to support their use; amantadine is the only therapy recommended by current clinical guidelines, specifically for patients with DoC caused by severe traumatic brain injury. To foster and advance development of consciousness-promoting therapies for patients with DoC, the Curing Coma Campaign convened a Coma Science Work Group to perform a gap analysis.<h4>Methods</h4>We consider five classes of therapies: (1) pharmacologiNeurocritical careTherapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions.PMC8266715RF1 NS115268DP2HD101400R21NS109627K23 NS114178DP2 HD101400R21 NS109627Hartings JAProvencio JJForeman BMayer SASnider SBRolston JDWhyte JAkbari YDiringer MNMcNett MWagner AVespa PSanz LRDOwen AMCuring Coma Campaign and its contributing membersLing GSFZiai WMonti MMEdlow BLPolizzotto LPark SGosseries OHelbok RThibaut AHemphill JCPouratian NBleck TPPuybasset LOlson DMStevens RDfalseTherapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions.<h4>Background/objective</h4>For patients with disorders of consciousness (DoC) and their families, the search for new therapies has been a source of hope and frustration. Almost all clinical trials in patients with DoC have been limited by small sample sizes, lack of placebo groups, and use of heterogeneous outcome measures. As a result, few therapies have strong evidence to support their use; amantadine is the only therapy recommended by current clinical guidelines, specifically for patients with DoC caused by severe traumatic brain injury. To foster and advance development of consciousness-promoting therapies for patients with DoC, the Curing Coma Campaign convened a Coma Science Work Group to perform a gap analysis.<h4>Methods</h4>We consider five classes of therapies: (1) pharmacologi2021-01-01T00:00:00Z2021 Jul2025-04-18T19:15:23.549Z2022-02-09T08:00:58.943ZS-EPMC82667153423662410.1007/s12028-021-01227-y